Epi Zyme Inc - Cambridge, Massachusetts 02139

Epi Zyme Inc is categorized under Commercial Biotechnical Research in Cambridge, MA .

Business Name: Epi Zyme Inc
Contact Person: Robert Gould, Chief Executive Officer
Address: 400 Technology Square # 4, Cambridge, Massachusetts 02139
Phone Number: (617) 500-7240
Website Address: epizyme.com
Annual Revenue (USD): $20.000.000 to $49.9999.999
Founding Year: 2007
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Commercial Biotechnical Research
SIC Code: 8731
NAICS Code: 3254120
Share This Business:
Related Businesses: Infinity Discovery Inc - Cambridge, MA 02139
Babyboost Inc - Cambridge, MA 02139
Visolis Inc - Cambridge, MA 02139
Volvox Biologic Inc - Cambridge, MA 02139
Manus Biosynthesis - Cambridge, MA 02139
Human Metabolome Technologies - Cambridge, MA 02139
Mersana Therapeutics Inc - Cambridge, MA 02139
Dna Medicine Institute Inc - Cambridge, MA 02139
Galenea Corp - Cambridge, MA 02139
Bluebird Bio Inc - Cambridge, MA 02139
Ariad Corp - Cambridge, MA 02139
Alantos Pharmaceuticals Inc - Cambridge, MA 02139
Rana Therapeutics Inc - Cambridge, MA 02139
Mindsjungle Inc - Cambridge, MA 02139
Warp Drive Bio LLC - Cambridge, MA 02139

The company Epi Zyme Inc provides B2B services in the form of Commercial Biotechnical Research from its single location in Massachusetts. 1 to 4 employees work for Epi Zyme Inc, and the business now earns $20.000.000 to $49.9999.999 per annum.

Epi Zyme Inc was launched in 2007 and is classified under SIC code and category 8731 , and NAICS number and grouping 3254120 . To contact Epi Zyme Inc, please call Robert Gould, Chief Executive Officer with the phone number (617) 500-7240 or visit its single location at 400 Technology Square # 4 in Cambridge, Massachusetts 02139.

The location of the single location can also be found using the coordinates 42.36369,-71.09117. Read more details about this business on the webpage epizyme.com or follow the company’s social media accounts, on Twitter and on Facebook.